Cargando…
Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865197/ https://www.ncbi.nlm.nih.gov/pubmed/36678575 http://dx.doi.org/10.3390/ph16010078 |
_version_ | 1784875776621936640 |
---|---|
author | Delbaere, Quentin Chapet, Nicolas Huet, Fabien Delmas, Clément Mewton, Nathan Prunier, Fabrice Angoulvant, Denis Roubille, François |
author_facet | Delbaere, Quentin Chapet, Nicolas Huet, Fabien Delmas, Clément Mewton, Nathan Prunier, Fabrice Angoulvant, Denis Roubille, François |
author_sort | Delbaere, Quentin |
collection | PubMed |
description | Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation. |
format | Online Article Text |
id | pubmed-9865197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98651972023-01-22 Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases Delbaere, Quentin Chapet, Nicolas Huet, Fabien Delmas, Clément Mewton, Nathan Prunier, Fabrice Angoulvant, Denis Roubille, François Pharmaceuticals (Basel) Brief Report Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation. MDPI 2023-01-04 /pmc/articles/PMC9865197/ /pubmed/36678575 http://dx.doi.org/10.3390/ph16010078 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Delbaere, Quentin Chapet, Nicolas Huet, Fabien Delmas, Clément Mewton, Nathan Prunier, Fabrice Angoulvant, Denis Roubille, François Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title | Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title_full | Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title_fullStr | Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title_full_unstemmed | Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title_short | Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases |
title_sort | anti-inflammatory drug candidates for prevention and treatment of cardiovascular diseases |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865197/ https://www.ncbi.nlm.nih.gov/pubmed/36678575 http://dx.doi.org/10.3390/ph16010078 |
work_keys_str_mv | AT delbaerequentin antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT chapetnicolas antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT huetfabien antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT delmasclement antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT mewtonnathan antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT prunierfabrice antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT angoulvantdenis antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases AT roubillefrancois antiinflammatorydrugcandidatesforpreventionandtreatmentofcardiovasculardiseases |